{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Neoplasms%2C+Recurrent", "query": { "condition": "Brain Neoplasms, Recurrent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 788, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Brain+Neoplasms%2C+Recurrent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T19:56:58.098Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT01622868", "title": "Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2012-12-06", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 292, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01622868" }, { "nct_id": "NCT00730262", "title": "Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "TLN-4601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thallion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-08", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2009-12-30", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 2, "location_summary": "New York, New York • Durham, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00730262" }, { "nct_id": "NCT01793168", "title": "Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rare Disorders", "Undiagnosed Disorders", "Disorders of Unknown Prevalence", "Cornelia De Lange Syndrome", "Prenatal Benign Hypophosphatasia", "Perinatal Lethal Hypophosphatasia", "Odontohypophosphatasia", "Adult Hypophosphatasia", "Childhood-onset Hypophosphatasia", "Infantile Hypophosphatasia", "Hypophosphatasia", "Kabuki Syndrome", "Bohring-Opitz Syndrome", "Narcolepsy Without Cataplexy", "Narcolepsy-cataplexy", "Hypersomnolence Disorder", "Idiopathic Hypersomnia Without Long Sleep Time", "Idiopathic Hypersomnia With Long Sleep Time", "Idiopathic Hypersomnia", "Kleine-Levin Syndrome", "Kawasaki Disease", "Leiomyosarcoma", "Leiomyosarcoma of the Corpus Uteri", "Leiomyosarcoma of the Cervix Uteri", "Leiomyosarcoma of Small Intestine", "Acquired Myasthenia Gravis", "Addison Disease", "Hyperacusis (Hyperacousis)", "Juvenile Myasthenia Gravis", "Transient Neonatal Myasthenia Gravis", "Williams Syndrome", "Lyme Disease", "Myasthenia Gravis", "Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)", "Isolated Klippel-Feil Syndrome", "Frasier Syndrome", "Denys-Drash Syndrome", "Beckwith-Wiedemann Syndrome", "Emanuel Syndrome", "Isolated Aniridia", "Axenfeld-Rieger Syndrome", "Aniridia-intellectual Disability Syndrome", "Aniridia - Renal Agenesis - Psychomotor Retardation", "Aniridia - Ptosis - Intellectual Disability - Familial Obesity", "Aniridia - Cerebellar Ataxia - Intellectual Disability", "Aniridia - Absent Patella", "Aniridia", "Peters Anomaly - Cataract", "Peters Anomaly", "Potocki-Shaffer Syndrome", "Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11", "Silver-Russell Syndrome Due to Imprinting Defect of 11p15", "Silver-Russell Syndrome Due to 11p15 Microduplication", "Syndromic Aniridia", "WAGR Syndrome", "Wolf-Hirschhorn Syndrome", "4p16.3 Microduplication Syndrome", "4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome", "Autosomal Recessive Stickler Syndrome", "Stickler Syndrome Type 2", "Stickler Syndrome Type 1", "Stickler Syndrome", "Mucolipidosis Type 4", "X-linked Spinocerebellar Ataxia Type 4", "X-linked Spinocerebellar Ataxia Type 3", "X-linked Intellectual Disability - Ataxia - Apraxia", "X-linked Progressive Cerebellar Ataxia", "X-linked Non Progressive Cerebellar Ataxia", "X-linked Cerebellar Ataxia", "Vitamin B12 Deficiency Ataxia", "Toxic Exposure Ataxia", "Unclassified Autosomal Dominant Spinocerebellar Ataxia", "Thyroid Antibody Ataxia", "Sporadic Adult-onset Ataxia of Unknown Etiology", "Spinocerebellar Ataxia With Oculomotor Anomaly", "Spinocerebellar Ataxia With Epilepsy", "Spinocerebellar Ataxia With Axonal Neuropathy Type 2", "Spinocerebellar Ataxia Type 8", "Spinocerebellar Ataxia Type 7", "Spinocerebellar Ataxia Type 6", "Spinocerebellar Ataxia Type 5", "Spinocerebellar Ataxia Type 4", "Spinocerebellar Ataxia Type 37", "Spinocerebellar Ataxia Type 36", "Spinocerebellar Ataxia Type 35", "Spinocerebellar Ataxia Type 34", "Spinocerebellar Ataxia Type 32", "Spinocerebellar Ataxia Type 31", "Spinocerebellar Ataxia Type 30", "Spinocerebellar Ataxia Type 3", "Spinocerebellar Ataxia Type 29", "Spinocerebellar Ataxia Type 28", "Spinocerebellar Ataxia Type 27", "Spinocerebellar Ataxia Type 26", "Spinocerebellar Ataxia Type 25", "Spinocerebellar Ataxia Type 23", "Spinocerebellar Ataxia Type 22", "Spinocerebellar Ataxia Type 21", "Spinocerebellar Ataxia Type 20", "Spinocerebellar Ataxia Type 2", "Spinocerebellar Ataxia Type 19/22", "Spinocerebellar Ataxia Type 18", "Spinocerebellar Ataxia Type 17", "Spinocerebellar Ataxia Type 16", "Spinocerebellar Ataxia Type 15/16", "Spinocerebellar Ataxia Type 14", "Spinocerebellar Ataxia Type 13", "Spinocerebellar Ataxia Type 12", "Spinocerebellar Ataxia Type 11", "Spinocerebellar Ataxia Type 10", "Spinocerebellar Ataxia Type 1 With Axonal Neuropathy", "Spinocerebellar Ataxia Type 1", "Spinocerebellar Ataxia - Unknown", "Spinocerebellar Ataxia - Dysmorphism", "Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature", "Spasticity-ataxia-gait Anomalies Syndrome", "Spastic Ataxia With Congenital Miosis", "Spastic Ataxia - Corneal Dystrophy", "Spastic Ataxia", "Rare Hereditary Ataxia", "Rare Ataxia", "Recessive Mitochondrial Ataxia Syndrome", "Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature", "Posterior Column Ataxia - Retinitis Pigmentosa", "Post-Stroke Ataxia", "Post-Head Injury Ataxia", "Post Vaccination Ataxia", "Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract", "Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus", "Non-hereditary Degenerative Ataxia", "Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity", "Olivopontocerebellar Atrophy - Deafness", "NARP Syndrome", "Myoclonus - Cerebellar Ataxia - Deafness", "Multiple System Atrophy, Parkinsonian Type", "Multiple System Atrophy, Cerebellar Type", "Multiple System Atrophy", "Maternally-inherited Leigh Syndrome", "Machado-Joseph Disease Type 3", "Machado-Joseph Disease Type 2", "Machado-Joseph Disease Type 1", "Leigh Syndrome", "Late-onset Ataxia With Dementia", "Infection or Post Infection Ataxia", "GAD Ataxia", "Hereditary Episodic Ataxia", "Gliadin/Gluten Ataxia", "Friedreich Ataxia", "Fragile X-associated Tremor/Ataxia Syndrome", "Familial Paroxysmal Ataxia", "Exposure to Medications Ataxia", "Episodic Ataxia With Slurred Speech", "Episodic Ataxia Unknown Type", "Episodic Ataxia Type 7", "Episodic Ataxia Type 6", "Episodic Ataxia Type 5", "Episodic Ataxia Type 4", "Episodic Ataxia Type 3", "Episodic Ataxia Type 1", "Epilepsy and/or Ataxia With Myoclonus as Major Feature", "Early-onset Spastic Ataxia-neuropathy Syndrome", "Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity", "Early-onset Cerebellar Ataxia With Retained Tendon Reflexes", "Early-onset Ataxia With Dementia", "Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia", "Dilated Cardiomyopathy With Ataxia", "Cataract - Ataxia - Deafness", "Cerebellar Ataxia, Cayman Type", "Cerebellar Ataxia With Peripheral Neuropathy", "Cerebellar Ataxia - Hypogonadism", "Cerebellar Ataxia - Ectodermal Dysplasia", "Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss", "Brain Tumor Ataxia", "Brachydactyly - Nystagmus - Cerebellar Ataxia", "Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia", "Autosomal Recessive Syndromic Cerebellar Ataxia", "Autosomal Recessive Spastic Ataxia With Leukoencephalopathy", "Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay", "Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria", "Autosomal Recessive Spastic Ataxia", "Autosomal Recessive Metabolic Cerebellar Ataxia", "Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine", "Autosomal Recessive Ataxia, Beauce Type", "Autosomal Recessive Ataxia Due to Ubiquinone Deficiency", "Autosomal Recessive Ataxia Due to PEX10 Deficiency", "Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia", "Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency", "Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency", "Autosomal Recessive Congenital Cerebellar Ataxia", "Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome", "Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity", "Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency", "Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect", "Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion", "Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation", "Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness", "Autosomal Recessive Cerebellar Ataxia", "Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly", "Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation", "Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy", "Autosomal Dominant Spastic Ataxia Type 1", "Autosomal Dominant Spastic Ataxia", "Autosomal Dominant Optic Atrophy", "Ataxia-telangiectasia Variant", "Ataxia-telangiectasia", "Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy", "Autosomal Dominant Cerebellar Ataxia Type 4", "Autosomal Dominant Cerebellar Ataxia Type 3", "Autosomal Dominant Cerebellar Ataxia Type 2", "Autosomal Dominant Cerebellar Ataxia Type 1", "Autosomal Dominant Cerebellar Ataxia", "Ataxia-telangiectasia-like Disorder", "Ataxia With Vitamin E Deficiency", "Ataxia With Dementia", "Ataxia - Oculomotor Apraxia Type 1", "Ataxia - Other", "Ataxia - Genetic Diagnosis - Unknown", "Acquired Ataxia", "Adult-onset Autosomal Recessive Cerebellar Ataxia", "Alcohol Related Ataxia", "Multiple Endocrine Neoplasia", "Multiple Endocrine Neoplasia Type II", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Multiple Endocrine Neoplasia, Type IV", "Multiple Endocrine Neoplasia, Type 3", "Multiple Endocrine Neoplasia (MEN) Syndrome", "Multiple Endocrine Neoplasia Type 2B", "Multiple Endocrine Neoplasia Type 2A", "Atypical Hemolytic Uremic Syndrome", "Atypical HUS", "Wiedemann-Steiner Syndrome", "Breast Implant-Associated Anaplastic Large Cell Lymphoma", "Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)", "Hemophagocytic Lymphohistiocytosis", "Behcet's Disease", "Alagille Syndrome", "Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)", "Lowe Syndrome", "Pitt Hopkins Syndrome", "1p36 Deletion Syndrome", "Jansen Type Metaphyseal Chondrodysplasia", "Cockayne Syndrome", "Chronic Recurrent Multifocal Osteomyelitis", "CRMO", "Malan Syndrome", "Hereditary Sensory and Autonomic Neuropathy Type Ie", "VCP Disease", "Hypnic Jerking", "Sleep Myoclonus", "Mollaret Meningitis", "Recurrent Viral Meningitis", "CRB1", "Leber Congenital Amaurosis", "Retinitis Pigmentosa", "Rare Retinal Disorder", "KCNMA1-Channelopathy", "Primary Biliary Cirrhosis", "ZMYND11", "Transient Global Amnesia", "Glycogen Storage Disease", "Alstrom Syndrome", "White Sutton Syndrome", "DNM1", "EIEE31", "Myhre Syndrome", "Recurrent Respiratory Papillomatosis", "Laryngeal Papillomatosis", "Tracheal Papillomatosis", "Refsum Disease", "Nicolaides Baraitser Syndrome", "Leukodystrophy", "Tango2", "Cauda Equina Syndrome", "Rare Gastrointestinal Disorders", "Achalasia-Addisonian Syndrome", "Achalasia Cardia", "Achalasia Icrocephaly Syndrome", "Anal Fistula", "Congenital Sucrase-Isomaltase Deficiency", "Eosinophilic Gastroenteritis", "Idiopathic Gastroparesis", "Hirschsprung Disease", "Rare Inflammatory Bowel Disease", "Intestinal Pseudo-Obstruction", "Scleroderma", "Short Bowel Syndrome", "Sacral Agenesis", "Sacral Agenesis Syndrome", "Caudal Regression", "Scheuermann Disease", "SMC1A Truncated Mutations (Causing Loss of Gene Function)", "Cystinosis", "Juvenile Nephropathic Cystinosis", "Nephropathic Cystinosis", "Kennedy Disease", "Spinal Bulbar Muscular Atrophy", "Warburg Micro Syndrome", "Mucolipidoses", "Mitochondrial Diseases", "Mitochondrial Aminoacyl-tRNA Synthetases", "Mt-aaRS Disorders", "Hypertrophic Olivary Degeneration", "Non-Ketotic Hyperglycinemia", "Fish Odor Syndrome", "Halitosis", "Isolated Congenital Asplenia", "Lambert Eaton (LEMS)", "Biliary Atresia", "STAG1 Gene Mutation", "Coffin Lowry Syndrome", "Borjeson-Forssman-Lehman Syndrome", "Blau Syndrome", "Arginase 1 Deficiency", "HSPB8 Myopathy", "Beta-Mannosidosis", "TBX4 Syndrome", "DHDDS Gene Mutations", "MAND-MBD5-Associated Neurodevelopmental Disorder", "Constitutional Mismatch Repair Deficiency (CMMRD)", "SPATA5 Disorder", "SPATA5L1 Related Disorder", "Acrodysostosis", "Multi-systematic Smooth Muscle Dysfunction Syndrome", "CRELD1 (Cysteine Rich With EGF Like Domains 1)", "GNB1 Syndrome", "Pyruvate Dehydrogenase Complex Deficiency Disease", "Beta Mannosidosis", "Kbg Syndrome", "Labrune Syndrome", "Metachromatic Leukodystrophy (MLD)", "Moyamoya Disease", "OPHN1 Syndrome", "Oculopharyngeal Muscular Dystrophy (OPMD)", "TUBB3 Mutation", "WOREE (WWOX-related Epileptic Encephalopathy", "SCAR12", "Skraban-Deardorff Syndrome", "Hereditary Myopathy With Early Respiratory Failure" ], "interventions": [], "intervention_types": [], "sponsor": "Sanford Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20000, "start_date": "2010-07", "completion_date": "2100-12", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01793168" }, { "nct_id": "NCT01189240", "title": "RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2010-12", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189240" }, { "nct_id": "NCT00362921", "title": "Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "Gliadel wafers in combination with O6-benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2004-04", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-07-10", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362921" }, { "nct_id": "NCT01748149", "title": "Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 40, "start_date": "2014-04-29", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 20, "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748149" }, { "nct_id": "NCT00227032", "title": "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-09", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227032" }, { "nct_id": "NCT00073944", "title": "BCX-1777 in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "forodesine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-09-02T19:56:58.098Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073944" } ] }